Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ administration & dosage
Carcinoma, Squamous Cell
/ drug therapy
Cetuximab
/ administration & dosage
Female
Follow-Up Studies
Head and Neck Neoplasms
/ drug therapy
Humans
Incidence
Lung Diseases, Interstitial
/ classification
Male
Middle Aged
Retrospective Studies
Risk Factors
Severity of Illness Index
Smoking
/ adverse effects
Young Adult
KL-6
cetuximab
head and neck cancer
interstitial lung disease
pack-years of smoking
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
21
08
2018
revised:
15
01
2019
accepted:
19
02
2019
pubmed:
5
3
2019
medline:
3
11
2020
entrez:
5
3
2019
Statut:
ppublish
Résumé
Interstitial lung disease (ILD) is known as a potentially severe adverse event associated with epidermal growth factor receptor (EGFR)-targeted therapy. The incidence and risk factors of ILD in patients with head and neck squamous cancer (HNSCC) treated with cetuximab, an anti-EGFR monoclonal antibody, have not been established. We retrospectively reviewed patients with HNSCC who received cetuximab from December 2012 to December 2016 at our institute and evaluated the incidence and risk factors of ILD. Of the 201 patients with HNSCC, ILD was observed in 9 patients (4.5%), 8 of whom had grade 3 or higher. High Krebs von den Lungen-6 (KL-6) and ≥50 pack-years of smoking were significantly predictive of associated with ILD (P = 0.00011 and 0.05, respectively). The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL-6 and smoking histories might be predictive for ILD among patients with HNSCC.
Sections du résumé
BACKGROUND
Interstitial lung disease (ILD) is known as a potentially severe adverse event associated with epidermal growth factor receptor (EGFR)-targeted therapy. The incidence and risk factors of ILD in patients with head and neck squamous cancer (HNSCC) treated with cetuximab, an anti-EGFR monoclonal antibody, have not been established.
METHODS
We retrospectively reviewed patients with HNSCC who received cetuximab from December 2012 to December 2016 at our institute and evaluated the incidence and risk factors of ILD.
RESULTS
Of the 201 patients with HNSCC, ILD was observed in 9 patients (4.5%), 8 of whom had grade 3 or higher. High Krebs von den Lungen-6 (KL-6) and ≥50 pack-years of smoking were significantly predictive of associated with ILD (P = 0.00011 and 0.05, respectively).
CONCLUSION
The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL-6 and smoking histories might be predictive for ILD among patients with HNSCC.
Substances chimiques
Antineoplastic Agents, Immunological
0
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2574-2580Informations de copyright
© 2019 Wiley Periodicals, Inc.